Immunofusion is a privately funded biotech established in 2019 by antibody engineering and Cell\DNA-therapy experts. Our academic background includes CAR T-cell and DNA-vaccine development from bench to bedside and the proprietary extra-large humanized nanobody library that yields specific and high affinity binders. We are focused on the development of two platforms - CAR T-cell therapy for the unment medical needs in CLL and MCL and DNA-encoded immunocytokines for the treatment of solid tumors.